Chris Seagle; PhD, MBA

My career has been centered on advancing market access, pricing, health economics and outcomes research (HEOR), and portfolio strategy as critical pillars of success in the biopharma industry. I have led access and pricing initiatives at large multinational organizations and steered strategy for agile biotech startups, developing scalable solutions that optimize patient access and maximize product value across oncology, hematology, immunology, rare diseases, and biosimilars.

Over the years, I have established dynamic market access teams and governance frameworks that embed access and pricing strategies into organizational pipelines, portfolios, and business development efforts. Whether managing pre-launch analytics, driving pricing innovation, or crafting access solutions for novel therapies, I have played a pivotal role in U.S. and global product launches.

I have worked with influential organizations such as AbbVie, Sanofi, EMD Serono, Coherus Biosciences, PTC Therapeutics, Eagle Pharmaceuticals, Simon-Kucher & Partners, and Bridgehead International. These experiences have provided a foundation for evidence-driven strategies and stakeholder alignment, enabling success in complex healthcare ecosystems.

My academic background further enhances my ability to bridge scientific innovation and commercial execution. I hold a Ph.D. and M.S. in biomedical engineering, an MBA, and a B.S. in Chemistry. This multidisciplinary education equips me with the technical and strategic expertise needed to craft solutions that align clinical development with market access priorities, delivering measurable impact for patients and stakeholders.

At the heart of my leadership philosophy is collaboration. I believe market access is not just a tactical function but an organizational mindset that transforms how companies engage strategy. By fostering partnerships and aligning cross-functional teams on shared goals, I aim to develop ecosystems where innovative market access solutions thrive from pipeline to loss-of-exclusivity.

Looking ahead, I am passionate about advancing patient access and developing forward-thinking strategies that meet the challenges of today’s evolving healthcare landscape. My focus remains on delivering impactful results for patients, stakeholders, and the biopharma industry.

Email Me:

Schedule
an Introduction:

Connect
With Me: